The Development of New Drug Delivery Systems to Treat Tumors Affecting the Central Nervous System
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".
Deadline for manuscript submissions: 30 September 2024 | Viewed by 171
Special Issue Editors
Interests: nanomedicine; nanotechnology; nanoparticles; hydrogels; stimuli-responsive hydrogels; controlled release; drug delivery; gene delivery; cancer targeting; pharmaceutical sciences
Special Issues, Collections and Topics in MDPI journals
Interests: nanomedicine; drug delivery; pharmaceutical technology; targeted therapies; cancer; personalized medicine
Special Issue Information
Dear Colleagues,
Tumors affecting the central nervous system (CNS, brain, and spinal cord) present an incidence of 321,731 new cases, being responsible for 248,500 deaths annually. Moreover, these tumors are the most common solid neoplasms and the leading cause of death from cancer in children, accounting for approximately 20% of childhood cancers. The advances observed in recent years, both in diagnostic and therapeutic aspects, improved the clinical outcomes; however, they are still insufficient, and some CNS tumors such as glioblastoma are still considered clinically unmet due to the lack of effective therapeutic options. The presence of the blood–brain barrier limits the doses of chemotherapy that can reach the tumors, leading to unsatisfactory therapeutic activity. For this reason, surgical resection is still a common therapeutic approach to treat CNS tumors. However, due to the complex nature and biological importance of the CNS, some tumors are non-operable, and/or total resection is not possible without affecting the normal and vital functions. This emphasizes the need for new and improved therapeutic approaches for the management and treatment of CNS tumors. This Special Issue intends to explore the most recent drug delivery systems developed to treat tumors affecting the central nervous system that could bring new hope for treatment.
Dr. Diana Rafael
Dr. Fernanda Andrade
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- central nervous systems
- cancer
- drug delivery systems
- clinical unmet need
